Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - CNS tumours

362O - Perifocal edema volume correlates with density of tumour-infiltrating cytotoxic T cells in newly diagnosed glioblastoma

Date

20 Sep 2020

Session

Proffered Paper - CNS tumours

Presenters

Maximilian Mair

Citation

Annals of Oncology (2020) 31 (suppl_4): S396-S408. 10.1016/annonc/annonc269

Authors

M.J. Mair1, K. Häller1, G.J. Kührer2, K. Feldmann1, B. Kiesel3, A. Wöhrer4, G. Widhalm3, J. Furtner-Srajer2, M. Preusser1, A.S. Berghoff1

Author affiliations

  • 1 Division Of Oncology / Department Of Medicine I, Medical University of Vienna, 1090 - Vienna/AT
  • 2 Division Of Neuroradiology And Musculoskeletal Radiology / Department Of Biomedical Imaging And Image-guided Therapy, Medical University of Vienna, 1090 - Vienna/AT
  • 3 Department Of Neurosurgery, Medical University of Vienna, 1090 - Vienna/AT
  • 4 Division Of Neuropathology And Neurochemistry / Department Of Neurology, Medical University of Vienna, 1090 - Vienna/AT
More

Resources

Login to access the resources on OncologyPRO.

Abstract 362O

Background

Edema is a hallmark of inflammation. Therefore, we explored the correlation of the peritumoral edema with tumor-infiltrating lymphocyte (TIL) density in newly diagnosed glioblastoma.

Methods

133 patients (60.9% male; 39.1% female) with histologically verified newly diagnosed glioblastoma were included in this study. The volume of peritumoral non-enhancing T2-hyperintense signal abnormalities was measured to quantify edema and non-enhancing tumor tissue. CD3+, CD8+ and PD-1+ TIL densities were analyzed using immunohistochemistry and tissue phenomics software.

Results

Median perifocal edema volume was 84200 mm3 (range: 442.4 – 254700). Median TIL densities were 74.7 cells/mm2 for CD3+ (range: 3.1 – 1071.4), 29.6 cells/mm2 for CD8+ (range: 3.0 – 290.3) and 13.6 cells/mm2 for PD-1+ TILs (range: 1.6 – 141.5). Strong correlation between CD3+ and CD8+ TIL densities was observed (Spearman’s r = 0.784, p < 0.001), furthermore PD-1+ TIL density correlated with CD3+ (r = 0.591, p < 0.001) and CD8+ (r = 0.532, p < 0.001) TIL densities. Larger than median perifocal edema volume correlated with higher CD8+ (p = 0.036) and tendentially higher PD-1+ TIL densities (p = 0.199), but not with CD3+ TIL density (p = 0.883). Among 84 patients with known methylguanine methyltransferase (MGMT) promoter methylation status, 33 (39.3%) patients with MGMT promoter hypermethylation had less perifocal edema than their unmethylated counterparts (n = 51/84, 60.7%; median: 84200 mm3 vs. 122400 mm3; p = 0.047), while there was no significant difference in CD3+, CD8+ and PD-1+ TIL density according to MGMT promoter methylation status.

Conclusions

Peritumoral non-enhancing T2-hyperintense signal abnormality volumes correlate with the density of intra-tumoral cytotoxic T cells in newly diagnosed glioblastoma and may serve as “immuno-radiomic” surrogate parameter.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Roche (unrestricted grant), Medical University of Vienna (research budget).

Disclosure

M. Preusser: Honoraria (self), Advisory/Consultancy: Bayer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Gerson Lehrman Group (GLG); Honoraria (self), Advisory/Consultancy: CMC Contrast; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): GlaxoSmithKline; Honoraria (self), Advisory/Consultancy: Mundipharma; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Roche; Honoraria (self), Advisory/Consultancy: BMJ Journals; Honoraria (self), Advisory/Consultancy: MedMedia; Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): AbbVie; Honoraria (self), Advisory/Consultancy: Lilly; Honoraria (self), Advisory/Consultancy: Medahead; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Daiichi Sankyo; Honoraria (self), Advisory/Consultancy: Sanofi; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Merck Sharp & Dohme; Honoraria (self), Advisory/Consultancy: Tocagen; Research grant/Funding (institution): Boehringer Ingelheim; Research grant/Funding (institution): Novocure. A.S. Berghoff: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Daiichi Sankyo; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy: Merck; Travel/Accommodation/Expenses: Amgen; Travel/Accommodation/Expenses: AbbVie. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings